SG11201903602RA - Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody - Google Patents
Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibodyInfo
- Publication number
- SG11201903602RA SG11201903602RA SG11201903602RA SG11201903602RA SG11201903602RA SG 11201903602R A SG11201903602R A SG 11201903602RA SG 11201903602R A SG11201903602R A SG 11201903602RA SG 11201903602R A SG11201903602R A SG 11201903602RA SG 11201903602R A SG11201903602R A SG 11201903602RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cancer
- dkk
- antibody
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413198P | 2016-10-26 | 2016-10-26 | |
| PCT/US2017/058555 WO2018081437A1 (fr) | 2016-10-26 | 2017-10-26 | Utilisation de la bêta-caténine en tant que biomarqueur pour traiter des cancers à l'aide d'un anticorps anti-dkk-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903602RA true SG11201903602RA (en) | 2019-05-30 |
Family
ID=60570180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903602RA SG11201903602RA (en) | 2016-10-26 | 2017-10-26 | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11267876B2 (fr) |
| EP (1) | EP3532099A1 (fr) |
| JP (2) | JP7374765B2 (fr) |
| KR (1) | KR20190085935A (fr) |
| CN (1) | CN110114087A (fr) |
| AU (1) | AU2017347822A1 (fr) |
| BR (1) | BR112019008279A2 (fr) |
| CA (1) | CA3041325A1 (fr) |
| IL (1) | IL266199A (fr) |
| MA (1) | MA46673A (fr) |
| MX (1) | MX2019004940A (fr) |
| RU (1) | RU2019115946A (fr) |
| SG (1) | SG11201903602RA (fr) |
| WO (1) | WO2018081437A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019115946A (ru) | 2016-10-26 | 2020-11-27 | Лип Терапьютикс, Инк. | Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 |
| AU2020216494A1 (en) * | 2019-02-01 | 2021-08-12 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against MHC-bound human Dickkopf-1 peptides and uses thereof |
| WO2021055789A1 (fr) * | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Utilisation d'inhibiteurs de dkk-1 pour le traitement du cancer |
| JP2023502666A (ja) * | 2019-11-22 | 2023-01-25 | リープ セラピューティクス，インコーポレイテッド | Ｄｋｋ－１阻害剤を用いて癌を処置する方法 |
| WO2023183940A2 (fr) * | 2022-03-24 | 2023-09-28 | The Translational Genomics Research Institute | Inhibiteurs peptidiques ciblant le complexe tbl1-beta-caténine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7446181B2 (en) * | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| WO2008097510A1 (fr) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Anticorps spécifiques de dkk-1 |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| CN103608037B (zh) * | 2011-02-01 | 2016-04-13 | 香港大学 | 抗dkk1单克隆抗体用于治疗肝癌的用途 |
| ES2703208T3 (es) | 2013-02-27 | 2019-03-07 | Daiichi Sankyo Co Ltd | Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK |
| CA2931975A1 (fr) * | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt |
| RU2019115946A (ru) | 2016-10-26 | 2020-11-27 | Лип Терапьютикс, Инк. | Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 |
-
2017
- 2017-10-26 RU RU2019115946A patent/RU2019115946A/ru unknown
- 2017-10-26 MA MA046673A patent/MA46673A/fr unknown
- 2017-10-26 SG SG11201903602RA patent/SG11201903602RA/en unknown
- 2017-10-26 EP EP17808633.6A patent/EP3532099A1/fr active Pending
- 2017-10-26 JP JP2019522823A patent/JP7374765B2/ja active Active
- 2017-10-26 BR BR112019008279A patent/BR112019008279A2/pt unknown
- 2017-10-26 CA CA3041325A patent/CA3041325A1/fr active Pending
- 2017-10-26 CN CN201780071597.0A patent/CN110114087A/zh active Pending
- 2017-10-26 MX MX2019004940A patent/MX2019004940A/es unknown
- 2017-10-26 KR KR1020197014600A patent/KR20190085935A/ko not_active Application Discontinuation
- 2017-10-26 AU AU2017347822A patent/AU2017347822A1/en active Pending
- 2017-10-26 US US16/345,191 patent/US11267876B2/en active Active
- 2017-10-26 WO PCT/US2017/058555 patent/WO2018081437A1/fr unknown
-
2019
- 2019-04-23 IL IL266199A patent/IL266199A/en unknown
-
2022
- 2022-01-28 US US17/587,708 patent/US20220289831A1/en active Pending
-
2023
- 2023-07-26 JP JP2023121862A patent/JP2023133432A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110114087A (zh) | 2019-08-09 |
| JP2023133432A (ja) | 2023-09-22 |
| JP2019533693A (ja) | 2019-11-21 |
| AU2017347822A1 (en) | 2019-05-09 |
| US20190284264A1 (en) | 2019-09-19 |
| MA46673A (fr) | 2019-09-04 |
| US11267876B2 (en) | 2022-03-08 |
| MX2019004940A (es) | 2019-09-26 |
| IL266199A (en) | 2019-06-30 |
| RU2019115946A (ru) | 2020-11-27 |
| JP7374765B2 (ja) | 2023-11-07 |
| BR112019008279A2 (pt) | 2019-07-09 |
| EP3532099A1 (fr) | 2019-09-04 |
| KR20190085935A (ko) | 2019-07-19 |
| US20220289831A1 (en) | 2022-09-15 |
| CA3041325A1 (fr) | 2018-05-03 |
| RU2019115946A3 (fr) | 2021-01-26 |
| WO2018081437A1 (fr) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201903602RA (en) | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases |